TY - JOUR
T1 - Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation
AU - Guardia-Laguarta, Cristina
AU - Pera, Marta
AU - Clarimón, Jordi
AU - Molinuevo, José Luis
AU - Sánchez-Valle, Raquel
AU - Lladó, Albert
AU - Coma, Mireia
AU - Gómez-Isla, Teresa
AU - Blesa, Rafael
AU - Ferrer, Isidre
AU - Lleó, Alberto
PY - 2010/1/1
Y1 - 2010/1/1
N2 - We report the clinical, pathologic, and biochemical characteristics of the recently described amyloid precursor protein (APP) I716F mutation. We present the clinical findings of individuals carrying the APP I716F mutation and the neuropathologic examination of the proband. The mutation was found in a patient with Alzheimer disease with onset at the age of 31 years and death at age 36 years and who had a positive family history of early-onset Alzheimer disease. Neuropathologic examination showed abundant diffuse amyloid plaques mainly composed of amyloid-β42 and widespread neurofibrillary pathology. Lewy bodies were found in the amygdala. Chinese hamster ovary cells transfected with this mutation showed a marked increase in the amyloid-β42/40 ratio and APP C-terminal fragments and a decrease in APP intracellular domain production, suggesting reduced APP proteolysis by γ-secretase. Taken together, these findings indicate that the APP I716F mutation is associated with the youngest age of onset for this locus and strengthen the inverse association between amyloid-β42/40 ratio and age of onset. The mutation leads to a protein that is poorly processed by γ-secretase. This loss of function may be an additional mechanism by which some mutations around the γ-secretase cleavage site lead to familial Alzheimer disease. Copyright © 2009 by the American Association of Neuropathologists, Inc.
AB - We report the clinical, pathologic, and biochemical characteristics of the recently described amyloid precursor protein (APP) I716F mutation. We present the clinical findings of individuals carrying the APP I716F mutation and the neuropathologic examination of the proband. The mutation was found in a patient with Alzheimer disease with onset at the age of 31 years and death at age 36 years and who had a positive family history of early-onset Alzheimer disease. Neuropathologic examination showed abundant diffuse amyloid plaques mainly composed of amyloid-β42 and widespread neurofibrillary pathology. Lewy bodies were found in the amygdala. Chinese hamster ovary cells transfected with this mutation showed a marked increase in the amyloid-β42/40 ratio and APP C-terminal fragments and a decrease in APP intracellular domain production, suggesting reduced APP proteolysis by γ-secretase. Taken together, these findings indicate that the APP I716F mutation is associated with the youngest age of onset for this locus and strengthen the inverse association between amyloid-β42/40 ratio and age of onset. The mutation leads to a protein that is poorly processed by γ-secretase. This loss of function may be an additional mechanism by which some mutations around the γ-secretase cleavage site lead to familial Alzheimer disease. Copyright © 2009 by the American Association of Neuropathologists, Inc.
KW - α-Synuclein
KW - γ-Secretase
KW - Alzheimer disease
KW - Amyloid
KW - APP mutations
KW - Genetics
UR - https://www.scopus.com/pages/publications/74049112323
U2 - 10.1097/NEN.0b013e3181c6b84d
DO - 10.1097/NEN.0b013e3181c6b84d
M3 - Article
SN - 0022-3069
VL - 69
SP - 53
EP - 59
JO - Journal of Neuropathology and Experimental Neurology
JF - Journal of Neuropathology and Experimental Neurology
IS - 1
ER -